Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 4/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22203014 | 1.00 | MAP1LC3B (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL18910972 | 1.00 | MAP1LC3B (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19708322 | 1.00 | MAP1LC3B (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19681322 | 0.98 | SIRT2 (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19502733 | 0.94 | FAP (0.42) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL21013625 | 0.94 | SIRT5 (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL21943700 | 0.94 | FAP (0.42) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL22138815 | 0.93 | FAP (0.39) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL19708459 | 0.93 | SIRT5 (0.40) | MAP1LC3BFAPSIRT2SIRT1SIRT3 | |
| SCHEMBL21119089 | 0.93 | FAP (0.43) | MAP1LC3BFAPSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2023-05-04 | — | — | US | disclosed |
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | ARS Pharmaceuticals, Inc. | 2021-05-27 | — | — | US | disclosed |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200199242-A1 | CONSTRUCT-PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | ORBIMED ADVISORS LLC | 2020-06-25 | — | — | US | disclosed |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2019-05-16 | — | — | US | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239553-A1 | BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same | BCL2, BCL2L10, BAX | MAP1LC3B 151/4885FAP 4180/4885SIRT2 942/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | MAP1LC3B 183/4885FAP 3670/4885SIRT2 973/4885 |
| US-20230135723-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | MAP1LC3B 471/4885FAP 4580/4885SIRT2 3167/4885 |
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | MAP1LC3B 3751/4885FAP 4182/4885SIRT2 4743/4885 |
| US-20200246460-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | MAP1LC3B 196/4885FAP 3962/4885SIRT2 1593/4885 |
| US-20210154317-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, FCGR3B, FCGR1A | MAP1LC3B 1112/4885FAP 1050/4885SIRT2 4292/4885 |
| US-20190142941-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | MAP1LC3B 196/4885FAP 3962/4885SIRT2 1593/4885 |
| US-20200199242-A1 | CONSTRUCT-PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NGLY1, MICA, VIP | MAP1LC3B 4189/4885FAP 936/4885SIRT2 4707/4885 |
| US-20200121803-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD99, SLC3A2, CD63 | MAP1LC3B 471/4885FAP 4580/4885SIRT2 3167/4885 |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | MAP1LC3B 183/4885FAP 3670/4885SIRT2 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.